Aliskiren-induced QT interval prolongation

Gregory J. Peitz, Mark A. Malesker, S. George Sojka

Research output: Contribution to journalArticle

8 Scopus citations

Abstract

Aliskiren gained FDA approval for the treatment of hypertension in 2007. It is the first approved pharmaceutical to manage hypertension by direct renin inhibition. With the introduction of novel drugs and mechanisms of action comes the challenge of monitoring for new unreported adverse events. The side effect profile for aliskiren has not yet been fully described. We describe the first apparent report of aliskiren-induced QT prolongation resulting in torsades de pointes.

Original languageEnglish (US)
Pages (from-to)411-412
Number of pages2
JournalSouthern Medical Journal
Volume102
Issue number4
DOIs
StatePublished - Apr 1 2009

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Fingerprint Dive into the research topics of 'Aliskiren-induced QT interval prolongation'. Together they form a unique fingerprint.

  • Cite this